Cyclopamine attenuates acute warm ischemia reperfusion injury in cholestatic rat liver: Hope for marginal livers

Akshay Pratap, Ravikiran Panakanti, Ningning Yang, Ramasubramanian Lakshmi, Kian A. Modanlou, James D. Eason, Ram I. Mahato

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Cholestasis is a significant risk factor for immediate hepatic failure due to ischemia reperfusion (I/R) injury in patients undergoing liver surgery or transplantation. We recently demonstrated that inhibition of Hedgehog (Hh) signaling with cyclopamine (CYA) before I/R prevents liver injury. In this study we hypothesized that Hh signaling may modulate I/R injury in cholestatic rat liver. Cholestasis was induced by bile duct ligation (BDL). Seven days after BDL, rats were exposed to either CYA or vehicle for 7 days daily before being subjected to 30 min of ischemia and 4 h of reperfusion. Expression of Hh ligands (Sonic Hedgehog, Patched-1 and Glioblastoma-1), assessment of liver injury, neutrophil infiltration, cytokines, lipid peroxidation, cell proliferation and apoptosis were determined. Significant upregulation of Hh ligands was seen in vehicle treated BDL rats. I/R injury superimposed on these animals resulted in markedly elevated serum alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin accompanied with increased neutrophil recruitment and lipid peroxidation. Preconditioning with CYA reduced the histological damage and serum liver injury markers. CYA also reduced neutrophil infiltration, proinflammatory cytokines such as TNF-α and IL-1β expression of α-smooth muscle actin and type 1 collagen resulting in reduced fibrosis. Furthermore CYA treated animals showed reduced cholangiocyte proliferation, and apoptosis. Hepatoprotection by CYA was conferred by reduced activation of protein kinase B (Akt) and extracellular signal regulated kinase (ERK). Endogenous Hh signaling in cholestasis exacerbates inflammatory injury during liver I/R. Blockade of Hh pathway represents a clinically relevant novel approach to limit I/R injury in cholestatic marginal liver.

Original languageEnglish (US)
Pages (from-to)958-968
Number of pages11
JournalMolecular Pharmaceutics
Volume8
Issue number3
DOIs
StatePublished - Jun 6 2011

Fingerprint

Warm Ischemia
Hedgehogs
Reperfusion Injury
Liver
Neutrophil Infiltration
Cholestasis
Bile Ducts
Ligation
Wounds and Injuries
Lipid Peroxidation
Reperfusion
Ischemia
Apoptosis
Cytokines
Ligands
Proto-Oncogene Proteins c-akt
Extracellular Signal-Regulated MAP Kinases
Liver Failure
Glioblastoma
Aspartate Aminotransferases

Keywords

  • bile duct ligation
  • hepatocellular injury
  • partial ischemia reperfusion
  • preconditioning

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Cyclopamine attenuates acute warm ischemia reperfusion injury in cholestatic rat liver : Hope for marginal livers. / Pratap, Akshay; Panakanti, Ravikiran; Yang, Ningning; Lakshmi, Ramasubramanian; Modanlou, Kian A.; Eason, James D.; Mahato, Ram I.

In: Molecular Pharmaceutics, Vol. 8, No. 3, 06.06.2011, p. 958-968.

Research output: Contribution to journalArticle

Pratap, Akshay ; Panakanti, Ravikiran ; Yang, Ningning ; Lakshmi, Ramasubramanian ; Modanlou, Kian A. ; Eason, James D. ; Mahato, Ram I. / Cyclopamine attenuates acute warm ischemia reperfusion injury in cholestatic rat liver : Hope for marginal livers. In: Molecular Pharmaceutics. 2011 ; Vol. 8, No. 3. pp. 958-968.
@article{ca9021bff3014b738b96385943b2837b,
title = "Cyclopamine attenuates acute warm ischemia reperfusion injury in cholestatic rat liver: Hope for marginal livers",
abstract = "Cholestasis is a significant risk factor for immediate hepatic failure due to ischemia reperfusion (I/R) injury in patients undergoing liver surgery or transplantation. We recently demonstrated that inhibition of Hedgehog (Hh) signaling with cyclopamine (CYA) before I/R prevents liver injury. In this study we hypothesized that Hh signaling may modulate I/R injury in cholestatic rat liver. Cholestasis was induced by bile duct ligation (BDL). Seven days after BDL, rats were exposed to either CYA or vehicle for 7 days daily before being subjected to 30 min of ischemia and 4 h of reperfusion. Expression of Hh ligands (Sonic Hedgehog, Patched-1 and Glioblastoma-1), assessment of liver injury, neutrophil infiltration, cytokines, lipid peroxidation, cell proliferation and apoptosis were determined. Significant upregulation of Hh ligands was seen in vehicle treated BDL rats. I/R injury superimposed on these animals resulted in markedly elevated serum alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin accompanied with increased neutrophil recruitment and lipid peroxidation. Preconditioning with CYA reduced the histological damage and serum liver injury markers. CYA also reduced neutrophil infiltration, proinflammatory cytokines such as TNF-α and IL-1β expression of α-smooth muscle actin and type 1 collagen resulting in reduced fibrosis. Furthermore CYA treated animals showed reduced cholangiocyte proliferation, and apoptosis. Hepatoprotection by CYA was conferred by reduced activation of protein kinase B (Akt) and extracellular signal regulated kinase (ERK). Endogenous Hh signaling in cholestasis exacerbates inflammatory injury during liver I/R. Blockade of Hh pathway represents a clinically relevant novel approach to limit I/R injury in cholestatic marginal liver.",
keywords = "bile duct ligation, hepatocellular injury, partial ischemia reperfusion, preconditioning",
author = "Akshay Pratap and Ravikiran Panakanti and Ningning Yang and Ramasubramanian Lakshmi and Modanlou, {Kian A.} and Eason, {James D.} and Mahato, {Ram I.}",
year = "2011",
month = "6",
day = "6",
doi = "10.1021/mp200115v",
language = "English (US)",
volume = "8",
pages = "958--968",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Cyclopamine attenuates acute warm ischemia reperfusion injury in cholestatic rat liver

T2 - Hope for marginal livers

AU - Pratap, Akshay

AU - Panakanti, Ravikiran

AU - Yang, Ningning

AU - Lakshmi, Ramasubramanian

AU - Modanlou, Kian A.

AU - Eason, James D.

AU - Mahato, Ram I.

PY - 2011/6/6

Y1 - 2011/6/6

N2 - Cholestasis is a significant risk factor for immediate hepatic failure due to ischemia reperfusion (I/R) injury in patients undergoing liver surgery or transplantation. We recently demonstrated that inhibition of Hedgehog (Hh) signaling with cyclopamine (CYA) before I/R prevents liver injury. In this study we hypothesized that Hh signaling may modulate I/R injury in cholestatic rat liver. Cholestasis was induced by bile duct ligation (BDL). Seven days after BDL, rats were exposed to either CYA or vehicle for 7 days daily before being subjected to 30 min of ischemia and 4 h of reperfusion. Expression of Hh ligands (Sonic Hedgehog, Patched-1 and Glioblastoma-1), assessment of liver injury, neutrophil infiltration, cytokines, lipid peroxidation, cell proliferation and apoptosis were determined. Significant upregulation of Hh ligands was seen in vehicle treated BDL rats. I/R injury superimposed on these animals resulted in markedly elevated serum alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin accompanied with increased neutrophil recruitment and lipid peroxidation. Preconditioning with CYA reduced the histological damage and serum liver injury markers. CYA also reduced neutrophil infiltration, proinflammatory cytokines such as TNF-α and IL-1β expression of α-smooth muscle actin and type 1 collagen resulting in reduced fibrosis. Furthermore CYA treated animals showed reduced cholangiocyte proliferation, and apoptosis. Hepatoprotection by CYA was conferred by reduced activation of protein kinase B (Akt) and extracellular signal regulated kinase (ERK). Endogenous Hh signaling in cholestasis exacerbates inflammatory injury during liver I/R. Blockade of Hh pathway represents a clinically relevant novel approach to limit I/R injury in cholestatic marginal liver.

AB - Cholestasis is a significant risk factor for immediate hepatic failure due to ischemia reperfusion (I/R) injury in patients undergoing liver surgery or transplantation. We recently demonstrated that inhibition of Hedgehog (Hh) signaling with cyclopamine (CYA) before I/R prevents liver injury. In this study we hypothesized that Hh signaling may modulate I/R injury in cholestatic rat liver. Cholestasis was induced by bile duct ligation (BDL). Seven days after BDL, rats were exposed to either CYA or vehicle for 7 days daily before being subjected to 30 min of ischemia and 4 h of reperfusion. Expression of Hh ligands (Sonic Hedgehog, Patched-1 and Glioblastoma-1), assessment of liver injury, neutrophil infiltration, cytokines, lipid peroxidation, cell proliferation and apoptosis were determined. Significant upregulation of Hh ligands was seen in vehicle treated BDL rats. I/R injury superimposed on these animals resulted in markedly elevated serum alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin accompanied with increased neutrophil recruitment and lipid peroxidation. Preconditioning with CYA reduced the histological damage and serum liver injury markers. CYA also reduced neutrophil infiltration, proinflammatory cytokines such as TNF-α and IL-1β expression of α-smooth muscle actin and type 1 collagen resulting in reduced fibrosis. Furthermore CYA treated animals showed reduced cholangiocyte proliferation, and apoptosis. Hepatoprotection by CYA was conferred by reduced activation of protein kinase B (Akt) and extracellular signal regulated kinase (ERK). Endogenous Hh signaling in cholestasis exacerbates inflammatory injury during liver I/R. Blockade of Hh pathway represents a clinically relevant novel approach to limit I/R injury in cholestatic marginal liver.

KW - bile duct ligation

KW - hepatocellular injury

KW - partial ischemia reperfusion

KW - preconditioning

UR - http://www.scopus.com/inward/record.url?scp=79958273831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958273831&partnerID=8YFLogxK

U2 - 10.1021/mp200115v

DO - 10.1021/mp200115v

M3 - Article

C2 - 21491930

AN - SCOPUS:79958273831

VL - 8

SP - 958

EP - 968

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 3

ER -